Henry Mugerwa

1.3k total citations · 1 hit paper
23 papers, 351 citations indexed

About

Henry Mugerwa is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Henry Mugerwa has authored 23 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 7 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Henry Mugerwa's work include HIV/AIDS Research and Interventions (13 papers), HIV/AIDS drug development and treatment (9 papers) and HIV Research and Treatment (7 papers). Henry Mugerwa is often cited by papers focused on HIV/AIDS Research and Interventions (13 papers), HIV/AIDS drug development and treatment (9 papers) and HIV Research and Treatment (7 papers). Henry Mugerwa collaborates with scholars based in Uganda, United Kingdom and United States. Henry Mugerwa's co-authors include Cissy Kityo, Nicholas I. Paton, Arvind Kaimal, Anne Hoppé, Abraham Siika, Andrew Kambugu, Joseph Kagaayi, Agnes Kiragga, Stephen Walimbwa and James Hakim and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and PLoS ONE.

In The Last Decade

Henry Mugerwa

21 papers receiving 349 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

2024 47 citations Cissy Kityo, Ivan Mambule et al. The Lancet Infectious Diseases profile →

Peers

Countries citing papers authored by Henry Mugerwa

Since Specialization

Citations

This map shows the geographic impact of Henry Mugerwa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Mugerwa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Mugerwa more than expected).

Fields of papers citing papers by Henry Mugerwa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Mugerwa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Mugerwa. The network helps show where Henry Mugerwa may publish in the future.

Co-authorship network of co-authors of Henry Mugerwa

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Mugerwa. A scholar is included among the top collaborators of Henry Mugerwa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Mugerwa. Henry Mugerwa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial 2025 ·Nature Medicine ·Cissy Kityo, Ivan Mambule, (unknown), Simiso Sokhela, Henry Mugerwa, (unknown), Fiona V Cresswell, (unknown), Josphat Kosgei, Reena Shah, Logashvari Naidoo, (unknown), (unknown), (unknown), (unknown), (unknown), Veerle Van Eygen, (unknown), (unknown), Nicholas I. Paton, (unknown)	0
2	Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study 2025 ·Clinical Pharmacology & Therapeutics ·Amedeo De Nicolò, (unknown), Henry Mugerwa, (unknown), (unknown), (unknown), (unknown), Mohammed Lamorde, (unknown), Paolo Denti, (unknown), Gary Maartens, Helen McIlleron, Lubbe Wiesner, Saye Khoo, Catriona Waitt, Antonio D’Avolio	1
3	Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy 2024 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Maiara Camotti Montanha, (unknown), Catherine Orrell, Henry Mugerwa, Marco Siccardi, Paolo Denti, Catriona Waitt	4
4	Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial breakdown → 2024 ·The Lancet Infectious Diseases ·Cissy Kityo, Ivan Mambule, (unknown), Simiso Sokhela, Henry Mugerwa, (unknown), Fiona V Cresswell, (unknown), Josphat Kosgei, Reena Shah, Logashvari Naidoo, (unknown), (unknown), (unknown), Arvind Kaimal, (unknown), Veerle Van Eygen, (unknown), (unknown), Nicholas I. Paton, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	47
5	Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin 2023 ·Clinical Infectious Diseases ·(unknown), Henry Mugerwa, Marco Siccardi, Maiara Camotti Montanha, Mohammed Lamorde, Lubbe Wiesner, Antonio D’Avolio, Helen McIlleron, Edmund Wilkins, Amedeo De Nicolò, Gary Maartens, Saye Khoo, Cissy Kityo, Paolo Denti, Catriona Waitt	6
6	Ethical and practical considerations in HIV drug trial closure: perspectives of research staff in Uganda 2021 ·Research Ethics ·(unknown), Karen Cox, Henry Mugerwa, Catrin Evans	0
7	Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda 2021 ·AIDS Research and Therapy ·Hellen Musana, (unknown), Mary Nakafeero, Henry Mugerwa, Flavia Matovu Kiweewa, David Serwadda, Francis Ssali	10
8	Facilitated transition in HIV drug trial closure: A conceptual model for HIV post-trial care 2021 ·PLoS ONE ·(unknown), Karen Cox, Henry Mugerwa, Catrin Evans	2
9	Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa 2021 ·Malaria Journal ·Gilles Ndayisaba, Adoke Yeka, Kwaku Poku Asante, Martin P. Grobusch, Etienne Karita, Henry Mugerwa, Stephen Asiimwe, Abraham Oduro, Bakary Fofana, Seydou Doumbia, Jay Prakash Jain, (unknown), Gerd A. Kullak‐Ublick, Guoqin Su, E. Schmitt, Katalin Csermak, Preetam Gandhi, David Hughes	15
10	Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda 2021 ·PLoS ONE ·(unknown), Joseph Kagaayi, Fredrick Makumbi, Henry Mugerwa, Joseph K. B. Matovu	27
11	Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV 2021 ·New England Journal of Medicine ·Nicholas I. Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppé, Apolo Balyegisawa, Arvind Kaimal, Grace Mirembe, (unknown), (unknown), James Hakim, Henry Mugerwa, Abraham Siika, (unknown), Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu	91
12	Perceptions of Strategies and Intervention Approaches for HIV Self-Management among Ugandan Adolescents: A Qualitative Study 2019 ·Journal of the International Association of Providers of AIDS Care (JIAPAC) ·Massy Mutumba, Henry Mugerwa, Victor Musiime, (unknown), (unknown), (unknown), Rob Stephenson	9
13	Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda 2019 ·PLoS ONE ·(unknown), (unknown), Henry Mugerwa	33
14	Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators 2019 ·AIDS ·Loveleen Bansi‐Matharu, (unknown), Stephen R. Cole, Henry Mugerwa, (unknown), Jens Lundgren, (unknown), Colette Smith, Andrew Phillips	5
15	Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda 2019 ·Journal of the Association of Nurses in AIDS Care ·(unknown), Karen Cox, Henry Mugerwa, Catrin Evans	2
16	Perceptions of HIV Self-Management Roles and Challenges in Adolescents, Caregivers, and Health Care Providers 2019 ·Journal of the Association of Nurses in AIDS Care ·Massy Mutumba, Victor Musiime, Henry Mugerwa, (unknown), (unknown), (unknown), Rob Stephenson	10
17	Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy 2018 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Anne C. Melzer, Gary Collins, Anchalee Avihingsanon, Kristina Crothers, Nicholas E. Ingraham, Henry Mugerwa, Matti Ristola, Jonathan Shuter, Ken M. Kunisaki, (unknown)	16
18	High Prevalence of tuberculosis infection among medical students in Makerere University, Kampala: results of a cross sectional study 2013 ·Archives of Public Health ·Henry Mugerwa, Denis K. Byarugaba, (unknown), (unknown), Joan N. Kalyango, Charles Karamagi, Achilles Katamba	8
19	Response to Antiretroviral Therapy of HIV Type 1-Infected Children in Urban and Rural Settings of Uganda 2012 ·AIDS Research and Human Retroviruses ·Victor Musiime, Joshua Kayiwa, Mary Kiconco, (unknown), (unknown), Henry Mugerwa, M Abwola, (unknown), (unknown), (unknown), George Abongomera, (unknown), (unknown), Francis Kiweewa, Francis Ssali, Cissy Kityo, Robert Colebunders, Peter Mugyenyi	16
20	Performance of Frontloading for Smear Microscopy in the Diagnosis of Pulmonary Tuberculosis: A Cross-Sectional Study at a Referral Hospital in Uganda 2012 ·PLoS ONE ·(unknown), Joan N. Kalyango, William Worodria, Henry Mugerwa, (unknown), Benon Asiimwe	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact